ENAROY is an orally-active HIF-PH inhibitor that promotes erythropoiesis by accelerating the endogenous production of erythropoietin (EPO) and controlling the expression of molecules responsible for iron metabolism. The Phase 3 clinical studies confirmed the efficacy and safety of ENAROY in anemic patients with CKD not on dialysis, on peritoneal dialysis and on hemodialysis.
JT and Torii expect ENAROY to be a new option for the treatment of anemia associated with CKD in
Outline of approval
Product
Generic
Indications: Anemia associated with CKD
Dosage and Administration
For patients with CKD not on dialysis and on peritoneal dialysis; The recommended starting dose for adult patients is 2 mg taken orally once daily before a meal or at bedtime. Thereafter, the dose should be adjusted as appropriate depending on the patient's condition. The maximum dose is 8 mg per dose.
For patients with CKD on hemodialysis; The recommended starting dose for adult patients is 4 mg taken orally once daily before a meal or at bedtime. Thereafter, the dose should be adjusted as appropriate depending on the patient's condition. The maximum dose is 8 mg per dose.
ABOUT Anemia Associated with CKD
Anemia is one of the complications in CKD patients. The major cause of anemia in patients with CKD is considered to be a decreased ability to produce EPO in the kidney associated with renal dysfunction. Insufficient oxygen supply due to decreased erythrocyte counts associated with anemia decreases the energy production in organs and induces reduction in mobility and activities in daily life, which leads to a poor quality of life.
Contact:
Tel: +81-3-3582-3111
(C) 2020 Electronic News Publishing, source